United Kingdom· GB-APID-28054311000001106
Xultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pens
A insulin degludec and liraglutide product containing insulin degludec + liraglutide, registered in United Kingdom by Novo Nordisk Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Insulin degludec and liraglutide is registered in 12 of 19 countries.
Countries holding a registration under ATC A10AE56 (insulin degludec and liraglutide), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Insulin degludec and liraglutide · ATC A10AE56
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Insulin degludec + Liraglutide
- Manufacturer
- Novo Nordisk Ltd
- Country
- United Kingdom (GB)
- ATC code
- A10AE56
- ATC class
- Insulin degludec and liraglutide
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5017954002047
- gtin5712249124854
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec and liraglutide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXULTOPHYNovo Nordisk A/S, Bagsvaerd
- NorwayXultophyOrifarm AS
- SpainXULTOPHY 100 U/ML + 3,6 MG/ML SOLUCION INYECTABLENovo Nordisk A/S
- FinlandXultophyNovo Nordisk A/S
- FranceXULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectableNOVO NORDISK (DANEMARK)
- IrelandXultophy 100 units/mL + 3.6 mg/mL solution for injection.Novo Nordisk A/S
- IcelandXultophyNovo Nordisk A/S*
- NetherlandsXultophy 100 eenheden/ml + 3,6 mg/ml oplossing voor injectieNovo Nordisk A.S.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xultophy
- Norway · Xultophy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0ba74972-ef57-4a1f-85bb-aa7d5326fb13 GET /v1/drugs/0ba74972-ef57-4a1f-85bb-aa7d5326fb13?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "28054311000001106",
"desc": "Xultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pens (Novo Nordisk Ltd)",
"form": "Solution for injection",
"vpid": "28279611000001109",
"source": "dmd",
"vtm_id": "776341007",
"strength": "3.6 mg",
"substance": "Insulin degludec + Liraglutide",
"ingredient": "Liraglutide",
"supplier_code": "2080301000001101"
}See everything about insulin degludec and liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.